| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CRYbA1 |
| Uniprot No | P05813 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-215aa |
| 氨基酸序列 | METQAEQQEL ETLPTTKMAQ TNPTPGSLGP WKITIYDQEN FQGKRMEFTS SCPNVSERSF DNVRSLKVES GAWIGYEHTS FCGQQFILER GEYPRWDAWS GSNAYHIERL MSFRPICSAN HKESKMTIFE KENFIGRQWE ISDDYPSLQA MGWFNNEVGS MKIQSGAWVC YQYPGYRGYQ YILECDHHGG DYKHWREWGS HAQTSQIQSI RRIQQ |
| 预测分子量 | 25,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CRYBA1重组蛋白的模拟参考文献示例(仅供参考，建议通过学术数据库核实具体文献)：
---
1. **文献名称**: *"Expression and characterization of recombinant human βA1-crystallin in Escherichia coli"*
**作者**: Smith J., et al.
**摘要**: 研究报道了人源CRYBA1蛋白在大肠杆菌中的重组表达与纯化，通过优化诱导条件获得可溶性蛋白，并验证其热稳定性和聚集特性，为后续白内障相关突变研究提供基础。
2. **文献名称**: *"Structural analysis of CRYBA1 mutants linked to congenital cataracts using recombinant protein models"*
**作者**: Wang L., Zhang H., et al.
**摘要**: 通过重组CRYBA1突变体(如R12C、G18V)的表达与结晶，揭示了突变导致蛋白结构异常及分子间相互作用的破坏，阐明了其与先天性白内障发病的关联。
3. **文献名称**: *"Functional characterization of recombinant CRYBA1 in lens transparency maintenance"*
**作者**: Kumar R., et al.
**摘要**: 利用重组CRYBA1蛋白进行体外细胞实验，证明其在抑制晶状体上皮细胞凋亡中的作用，并发现氧化应激下蛋白聚集加剧，提示其在年龄相关性白内障中的病理机制。
4. **文献名称**: *"CRYBA1 recombinant protein rescue of lens defects in a zebrafish cataract model"*
**作者**: Chen X., Li Y., et al.
**摘要**: 在斑马鱼白内障模型中注射重组CRYBA1蛋白，观察到晶状体透明度部分恢复，证实外源CRYBA1对遗传性白内障的潜在治疗价值。
---
注：以上文献信息为示例性内容，实际引用时需通过PubMed、Google Scholar等平台检索真实文献并核对细节。
CRYbA1 (β-crystallin A1) is a member of the βγ-crystallin superfamily, a group of structural proteins predominantly expressed in the ocular lens. These proteins are essential for maintaining lens transparency and refractive properties by ensuring proper cellular organization and minimizing light scattering. CRYbA1. encoded by the *CRYBA1* gene in humans, is a critical component of the β-crystallin family, which constitutes ~35% of total lens crystallins. It plays a vital role in lens development and homeostasis, particularly in fiber cell differentiation and long-term protein stability.
Structurally, CRYbA1 adopts a conserved β-sheet "Greek key" motif, typical of crystallins, enabling tight packing and high solubility. It forms dimers or higher-order aggregates through interdomain interactions, contributing to the dense, ordered lattice required for lens clarity. Mutations in *CRYBA1* are linked to congenital cataracts, highlighting its functional importance. Over 20 pathogenic variants (e.g., p.G61R, p.S170G) disrupt protein folding, solubility, or interaction networks, leading to aggregation and lens opacity.
Recombinant CRYbA1 is produced via heterologous expression systems (e.g., *E. coli*, mammalian cells) for structural and functional studies. Its recombinant form enables investigations into cataract mechanisms, including misfolding pathways, chaperone interactions, and oxidative stress responses. Researchers also use it to screen potential therapeutics targeting crystallin aggregation. Additionally, CRYbA1 serves as a model for studying protein stability under physiological stress, given its evolutionary adaptation to resist denaturation in the long-lived lens environment. Recent studies explore its non-lens roles, such as in retinal regeneration, though its primary significance remains in understanding and treating lens disorders.
×
